Loading
When two cancer drugs are combined, each is usually given at its full single-agent dose, which often proves too toxic. Testing a grid of dose pairs would find combinations that work with tolerable side effects.
Combination phase 1/2 studies use model-based two-agent dose-finding (partial-order CRM, BOIN-COMB) or factorial randomised designs to explore dose pairs, with efficacy and tolerability read-outs at each pair, rather than fixing one agent at its label dose and escalating the other. Regulators expect a justification for each agent's dose in combination labels.
Shares Wrong doses, Small-molecule kinase inhibitors, Immune checkpoint inhibitors.
Shares Too many combinations to test, Wrong doses.
Shares Wrong doses, Small-molecule kinase inhibitors, Immune checkpoint inhibitors.
Shares Too many combinations to test, Wrong doses, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/